Press Releases

August 3, 2016

University of Pittsburgh Licenses Novel Microneedle Patch to Pittsburgh Company

SkinJect Microneedle Patch to Deliver Drug To Treat and Immunize Skin Cancer Patients

Pittsburgh, PA

SkinJect, Inc., a Pittsburgh-based company, today announced its completion of a license with the University of Pittsburgh to its novel, minimally invasive treatment for common forms of non-melanoma skin cancer, basal cell and squamous cell carcinoma. Two million new cases of basal cell cancer are reported each year in the United States, and more than half of all patients suffer a recurrence. The new product under development could dramatically change the way these skin cancers are treated.

Read More

The SkinJect patch is a thumb-sized array of dissolvable microneedles that will deliver a chemotherapeutic agent to kill an existing skin cancer. The SkinJect patch will be applied once a week, for three weeks, in the doctor’s office. The microneedles, less than a millimeter long, dissolve within 15 minutes of application.

Louis D. Falo, M.D., Ph.D., who chairs Pittsburgh’s Department of Dermatology, is a co-inventor of the microneedle patch, along with O. Burak Ozdoganlar, Ph.D., Professor in Mechanical Engineering and Materials Science and Engineering, Carnegie Mellon University. Both inventors serve as scientific advisors to the company as it develops the array.

“The SkinJect patch is a promising novel approach to combating cancer,” said Falo. “Right now, a standard of care for basal cell carcinoma is Mohs micrographic surgery, which can be expensive, painful, and disfiguring. The SkinJect patch will offer a cost-effective way to treat an existing cancer and potentially prevent it from coming back again later in life.”

President and CEO of SkinJect Jim Nolan said SkinJect was being watched closely by both the medical and investment communities. “This device has the potential to transform the fields of dermatology and oncology. Its commercial future is extremely promising,” said Nolan.

“We’re excited to have concluded this deal with a company headquartered in Pittsburgh,” said Marc Malandro, Founding Director of the University of Pittsburgh Innovation Institute, who also serves as Chairman of Pennsylvania Bio, the state’s life sciences trade organization. “A number of local biotech entrepreneurs – including Anthony Florence, who played a pivotal role in providing early seed money for this project – have supported SkinJect. The company’s success is an affirmation of our region’s growing biotech community.”

The company plans to file an IND (Investigational New Drug) application, a request to the FDA to begin administering the device to humans, by late 4th quarter 2016 or early 1st quarter 2017.

# # #

About SkinJect, Inc.
SkinJect is a novel, minimally invasive treatment for common forms of non-melanoma skin cancer, basal cell and squamous cell carcinoma. Based in Pittsburgh, SkinJect, Inc. has secured a licensing deal with the University of Pittsburgh for the product which is under development. The patch is made up of a thumb-sized array of dissolvable microneedles that delivers a chemotherapeutic agent to kill an existing skin cancer.

Show Less

June 9, 2016

SkinJect, Inc. Presents Novel Delivery System at Coulter Investment Forum

James Nolan Introduces SkinJect™ at Early-Stage Investment Event

Pittsburgh, PA

SkinJect, a novel delivery system that treats basal and squamous cell cancer, was introduced by President and CEO James M. Nolan, a seasoned life sciences executive, at the 2016 Coulter Investment Forum, held April 27-28, 2016 in Boston. The event brought in funders from life sciences and investment companies.

Read More

Coulter provided the initial funding to design the product. SkinJect, Inc., in partnership with The University of Pittsburgh, licensed the novel, minimally invasive device to treat the most common forms of non-melanoma skin cancer. SkinJect, Inc. was reviewed by the Translational Research Partnership Program through its partnership with the University, using the Coulter Commercialization Process – a requirement to be eligible for the event.

“The Coulter Investment Forum was the ideal venue for Jim to present SkinJect,” said Max Fedor, Coulter Program Director at University of Pittsburgh “SkinJect was featured alongside some extremely promising life science innovations, and it gave us the unique opportunity to showcase the product in front of multiple investors at once.”

In order to qualify for the event, companies had to meet several requirements:

  • Have an experienced CEO
  • Have an executed license or the option of IP
  • Solve an unmet clinical need

SkinJect currently has patents issued by the U.S. Patent and Trade Office covering the technology. It has also filed additional provisional patents along with international patent claims. The SkinJect microneedle array will offer a novel way to treat basal and squamous cell skin cancer, offering a simpler alternative to Mohs micrographic surgery, one of several current treatments.

Show Less